FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma

BACKGROUND: Metastatic renal cell carcinoma has a poor prognosis and an intrinsic resistance to standard treatment. Sunitinib is an oral receptor tyrosine kinase inhibitor that has been used as a first-line targeted therapy in metastatic renal cell carcinoma. While computed tomography (CT) is curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Horn, Kevin P., Yap, Jeffrey T., Agarwal, Neeraj, Morton, Kathryn A., Kadrmas, Dan J., Beardmore, Britney, Butterfield, Regan I., Boucher, Kenneth, Hoffman, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558962/
https://www.ncbi.nlm.nih.gov/pubmed/26335224
http://dx.doi.org/10.1186/s40644-015-0049-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558962/
https://www.ncbi.nlm.nih.gov/pubmed/26335224
http://dx.doi.org/10.1186/s40644-015-0049-x

Ejemplares similares